Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Provides Update on the FDA Review of EM-100","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Provides Update on the FDA Review of EM-100","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Duke University School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sen-Jam Pharmaceutical Partners with Leading Academic Medical Centers in Promising Novel Oral COVID-19 Therapeutic Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK-TECH, INC.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sen-Jam Pharmaceutical Partners with Specialty Pharmaceutical Manufacturer to Provide Formulation and Chemistry, Manufacturing & Controls for Covid-19 Oral Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK-TECH, INC.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KVK Tech Announces Phase II Trial of COVID-19 Oral Therapy is Currently Enrolling in Nepal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK-TECH, INC.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sen-Jam Pharmaceutical Opens Enrollment for Patients in Their COVID Therapy Phase 2 Clinical Trial in Nepal and Engages With Strategic Investor for Worldwide Distribution","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Ketotifen Fumarate

    Menu

    Ketotifen Fumarate

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Sen-Jam Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sen-Jam Pharmaceutical Opens Enrollment for Patients in Their COVID Therapy Phase 2 Clinical Trial in Nepal and Engages With Strategic Investor for Worldwide Distribution

              Details:

              SJP-002C (ketotifen) world most potent, orally available anti-inflammatory a person could obtain for a mild to moderate coronavirus infection, Sen-Jam's investigational therapeutic for treatment of COVID-19, SJP-002C is now actively enrolling patients for their clinical trial.

              Lead Product(s): Ketotifen Fumarate,Indomethacin

              Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: KVK-TECH, INC.

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sen-Jam Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              KVK Tech Announces Phase II Trial of COVID-19 Oral Therapy is Currently Enrolling in Nepal

              Details:

              KVK will have exclusive manufacturing and supply rights for the product SJP-002C (Ketotifen) in the US. Sen-Jam will utilize the finished formulation and CMC report to enter licensing deals with contracting manufacturing companies (CMOs) globally.

              Lead Product(s): Ketotifen Fumarate,Indomethacin

              Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: KVK-TECH, INC.

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sen-Jam Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sen-Jam Pharmaceutical Partners with Specialty Pharmaceutical Manufacturer to Provide Formulation and Chemistry, Manufacturing & Controls for Covid-19 Oral Therapeutic

              Details:

              Sen-Jam Pharmaceutical has entered a development, manufacturing, distribution, and license agreement with KVK-Tech. This is a monumental milestone for the company and great news for their promising oral COVID-19 treatment, SJP-002C.

              Lead Product(s): Ketotifen Fumarate,Indomethacin

              Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: KVK-TECH, INC.

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership March 22, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sen-Jam Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sen-Jam Pharmaceutical Partners with Leading Academic Medical Centers in Promising Novel Oral COVID-19 Therapeutic Clinical Trial

              Details:

              The collaboration received official approval this past Friday from the Nepal Health Research Council and is now commencing Phase II Clinical Trials of SJP-002C, for a novel oral therapy to mitigate the symptoms and hospitalizations associated with COVID-19.

              Lead Product(s): Ketotifen Fumarate,Indomethacin

              Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Duke University School of Medicine

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 22, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eton Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eton Pharmaceuticals Provides Update on the FDA Review of EM-100

              Details:

              EM-100 is an eye drop to ease itchy eyes from allergic conjunctivitis. Eton's partner has not yet received a communication from the U.S. Food and Drug Administration (FDA) regarding its decision on the review of EM-100.

              Lead Product(s): Ketotifen Fumarate

              Therapeutic Area: Ophthalmology Product Name: EM-100

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 16, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eton Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eton Pharmaceuticals Provides Update on the FDA Review of EM-100

              Details:

              U.S. Food and Drug Administration (FDA) regarding its decision on the review of EM-100. EM-100’s Generic Drug User Fee Act (GDUFA) target action date was August 10th.

              Lead Product(s): Ketotifen Fumarate

              Therapeutic Area: Ophthalmology Product Name: EM-100

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 11, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY